Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence

Blood

Volumn 121, Issue 16, 2013, Pages 3153-3160

  Bonn, Bettina R ^a   Rohde, Marius ^a   Zimmermann, Martin ^a   Krieger, David ^a   Oschlies, Ilske ^b   Niggli, Felix ^c   Wrobel, Grazyna ^d   Attarbaschi, Andishe ^e   Escherich, Gabriele ^f   Klapper, Wolfram ^b   Reiter, Alfred ^a   Burkhardt, Birgit ^a,g  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 RECEPTOR; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CHILDHOOD CANCER; CHROMOSOME 6Q; CHROMOSOME 9P; CLINICAL FEATURE; CONTROLLED STUDY; EVENT FREE SURVIVAL; EXON; FEMALE; FOLLOW UP; GENETIC VARIATION; HETEROZYGOSITY LOSS; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SCHOOL CHILD; T CELL LYMPHOBLASTIC LEUKEMIA CELL; CHROMOSOME 6; COHORT ANALYSIS; GENETIC VARIABILITY; GENETICS; INCIDENCE; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; T CELL LYMPHOMA;

ADOLESCENT; CELL CYCLE PROTEINS; CHILD; CHROMOSOMES, HUMAN, PAIR 6; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; F-BOX PROTEINS; FEMALE; GENETIC VARIATION; HUMANS; INCIDENCE; LOSS OF HETEROZYGOSITY; LYMPHOMA, T-CELL; MALE; MUTATION; PROGNOSIS; RECEPTOR, NOTCH1; UBIQUITIN-PROTEIN LIGASES;

MLCS; MLOWN;

EID: 84879149485     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-474148     Document Type: Article

References (50)

1. Patte C, Kalifa C, Flamant F, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20(2): 105-113.
2. Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24(3):491-499.
3. Uyttebroeck A, Suciu S, Laureys G, et al. Children’s Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC). Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer. 2008;44(6):840-846.
4. Abromowitch M, Sposto R, Perkins S, et al. Children’s Oncology Group. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology Group. Br J Haematol. 2008;143(2): 261-267.
5. Pillon M, Piglione M, Garaventa A, et al. AIEOP-NHL Committee. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer. 2009;53(6): 953-959.
6. Sandlund JT, Pui CH, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23(6):1127-1130.
7. Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874-883.
8. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol. 2009;27(20): 3363-3369.
9. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-271.
10. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4):1151-1157.
11. Park MJ, Taki T, Oda M, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009;145(2):198-206.
12. Larson Gedman A, Chen Q, Kugel Desmoulin S, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Leukemia. 2009;23(8):1417-1425.
13. Clappier E, Collette S, Grardel N, et al. EORTC-CLG. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia. 2010;24(12):2023-2031.
14. Zuurbier L, Homminga I, Calvert V, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014-2022.
15. Kox C, Zimmermann M, Stanulla M, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia. 2010;24(12):2005-2013.
16. Erbilgin Y, Sayitoglu M, Hatirnaz O, et al. Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL. Dis Markers. 2010; 28(6):353-360.
17. Basso K, Mussolin L, Lettieri A, et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011; 50(12):1063-1075.
18. Mansur MB, Hassan R, Barbosa TC, et al. Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia. BMC Cancer. 2012; 12(1):9.
19. Jenkinson S, Koo K, Mansour MR, et al. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia. 2013;27(1):41-47.
20. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol. 2011;223(2):262-273.
21. Li X, von Boehmer H. Notch signaling in T-cell development and T-ALL. ISRN Hematol. 2011; 2011: 921706.
22. O’Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813-1824.
23. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007; 204(8):1825-1835.
24. Baleydier F, Decouvelaere AV, Bergeron J, et al. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res. 2008;14(3):692-700.
25. Callens C, Baleydier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012; 30(16):1966-1973.
26. Burkhardt B, Bruch J, Zimmermann M, et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006;20(8):1422-1429.
27. Burkhardt B, Moericke A, Klapper W, et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma. 2008;49(3):451-461.
28. Borowitz MJ, Chan JKC. T lymphoblastic leukaemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:176-178.
29. Oschlies I, Burkhardt B, Chassagne-Clement C, et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011;35(6):836-844.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
31. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
32. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 1980.
33. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
34. Cox DR. Regression models and life-tables. J R Stat Soc [Ser A]. 1972;34(2):187-220.
35. Wagener C, Müller O. Molekulare Onkologie. Stuttgart, Germany: Thieme Verlag; 2009.
36. Krieger D, Moericke A, Oschlies I, et al. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica. 2010;95(1):158-162.
37. Orlicky S, Tang X, Willems A, et al. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell. 2003;112(2):243-256.
38. Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, et al. Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma. 2007;48(9): 1745-1754.
39. Lones MA, Heerema NA, Le Beau MM, et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet. 2007;172(1):1-11.
40. Heerema NA, Sather HN, Sensel MG, et al. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children’s Cancer Group. J Clin Oncol. 1998; 16(4):1270-1278.
41. Schneider NR, Carroll AJ, Shuster JJ, et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. Blood. 2000;96(7):2543-2549.
42. Feng H, Stachura DL, White RM, et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 2010; 18(4):353-366.
43. Mao JH, To MD, Perez-Losada J, et al. Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev. 2004; 18(15):1800-1805.
44. Jebar AH, Hurst CD, Tomlinson DC, et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24(33):5218-5225.
45. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. In: Rommel C, Vanhaesebroeck B, Vogt PK, eds. Phosphoinositide 3-kinase in Health and Disease. Heidelberg, Germany: Springer; 2010:21-42.
46. Thurber AE, Douglas G, Sturm EC, et al. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene. 2011;30(27):3036-3048.
47. Wu J, Lei G, Mei M, et al. A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing Protein 1 (DDRGK1) and modulates NF-kappaB signaling. J Biol Chem. 2010;285(20):15126-15136.
48. Liu H, Chiang MY, Pear WS. Critical roles of NOTCH1 in acute T-cell lymphoblastic leukemia. Int J Hematol. 2011;94(2):118-125.
49. Koch U, Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol. 2011;32(9): 434-442.
50. Miyata Y, Liu Y, Jankovic V, et al. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells. 2010;28(2):308-317.